Akademik Veri Yönetim Sistemi
BMC NEPHROLOGY, cilt.26, ss.1-8, 2025 (SCI-Expanded)
Atherosclerotic cardiovascular diseases are the leading causes of morbidity and mortality in patients undergoing peritoneal dialysis and hemodialysis due to end-stage renal disease. Dyslipidemia is a major contributing factor to the development of atherosclerotic cardiovascular diseases, and its prevention is recommended to reduce cardiovascular risk. Several studies have demonstrated the presence of dyslipidemia in patients with chronic kidney disease, and peritoneal dialysis patients have been observed to have a more atherogenic lipid profile compared to those receiving hemodialysis. One of the primary reasons for this is thought to be the absorption of glucose from peritoneal dialysis solutions. In this study, we aimed to assess dyslipidemia in peritoneal dialysis patients and investigate the relationship between glucose absorption from dialysis solutions and lipid profile alterations. A total of 73 patients followed up in the nephrology outpatient clinic were included. Patients’ lipid profiles, the types of dialysis solutions used, and their compositions were statistically analyzed. A statistically significant inverse correlation was found between the amount of glucose absorbed during peritoneal dialysis and HDL cholesterol levels, which was observed both in the overall peritoneal dialysis patient group and in the subgroup undergoing automated peritoneal dialysis (APD). However, no statistically significant relationship was found between glucose absorption and other lipid parameters. Our findings suggest that the glucose content of peritoneal dialysis solutions alone does not play a major role in the development of dyslipidemia when considering all atherogenic lipid parameters. Therefore, dyslipidemia in peritoneal dialysis patients should be evaluated by considering all contributing factors, including treatment-related effects and, in particular, the structural and functional characteristics of the peritoneal membrane